GeoVax Labs, a clinical-stage biotechnology company, will present its latest research developments at the 37th Annual Roth Conference in Dana Point, California. Chairman and CEO David Dodd will participate in a fireside chat on March 17, 2025, providing insights into the company's promising COVID-19 vaccine and oncology programs.
The company's lead COVID-19 vaccine candidate, GEO-CM04S1, is currently undergoing multiple Phase 2 clinical trials targeting diverse patient populations. These trials include evaluating the vaccine as a primary immunization for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a more robust alternative to existing mRNA vaccines.
GeoVax recently secured a BARDA-funded contract to sponsor a large-scale 10,000-participant Phase 2b clinical trial comparing GEO-CM04S1 against existing authorized COVID-19 vaccines, demonstrating significant potential for advancing pandemic response strategies.
Beyond its COVID-19 research, the company is also progressing in oncology. Its lead clinical program, Gedeptin®, is a novel oncolytic solid tumor gene-directed therapy. After completing a Phase 1/2 clinical trial for advanced head and neck cancers, GeoVax plans a Phase 2 trial combining Gedeptin® with an immune checkpoint inhibitor.
The Roth Conference presentation represents an opportunity for investors and researchers to gain deeper understanding of GeoVax's innovative approaches to vaccine development and cancer treatment, potentially signaling important advancements in medical research.
